Pneumocystis pneumonia

The 2025 EQUAL Pneumocystis Score—an ECMM tool to measure QUALity in Pneumocystis pneumonia management

mycolabadmin

Pneumocystis pneumonia is a serious lung infection that affects people with weakened immune systems, including those with HIV and transplant patients. Doctors use different guidelines to diagnose and treat this infection, but these guidelines are complex and can be hard to follow consistently. Researchers created a new scoring system called the EQUAL Pneumocystis Score that helps doctors follow the best treatment recommendations by assigning points for different diagnostic tests, medications, and follow-up strategies.

Fungal β-Glucans: Biological Properties, Immunomodulatory Effects, Diagnostic and Therapeutic Applications

mycolabadmin

β-glucans are beneficial compounds found in fungi and some plants that help your body in multiple ways. They boost your immune system, lower cholesterol and blood sugar, protect against oxidative stress, and may help fight cancer and infections. Recent research shows they could be useful as diagnostic markers for fungal infections and as vaccine boosters, especially for diseases like COVID-19.

Access to diagnostic testing for invasive fungal diseases and other opportunistic infections in Mexican health care centers caring for patients living with HIV

mycolabadmin

This study examined the availability of diagnostic tests for fungal and other serious infections in Mexican HIV clinics. Researchers found that most clinics, especially smaller primary care facilities, lack modern rapid testing equipment needed to quickly diagnose dangerous infections like cryptococcosis and histoplasmosis. These infections are common in people with advanced HIV and can be life-threatening, making access to rapid diagnosis crucial for treatment and survival.

Recent innovations and challenges in the treatment of fungal infections

mycolabadmin

Fungal infections are becoming more common and dangerous, especially for people with weakened immune systems, and many fungi are developing resistance to current medications. Doctors and researchers are developing new treatment strategies, including combining multiple drugs together and using advanced technologies to deliver medicines more effectively to infected areas. Natural compounds from plants and new biotechnology tools like genetic engineering and nanoparticles show promising results for fighting drug-resistant fungal infections.

Informing the World Health Organization Fungal Priority Pathogens List (WHO-FPPL): A collection of systematic reviews

mycolabadmin

The World Health Organization created a priority list of dangerous fungal infections affecting millions of people globally each year. Experts reviewed 19 different fungal pathogens and ranked them by how dangerous they are and how much they need research and treatment development. The list identifies which fungal infections should get the most attention from doctors, researchers, and public health officials to improve patient outcomes and reduce deaths.

The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective

mycolabadmin

Fungal infections affect over a billion people worldwide but are often overlooked in healthcare. The World Health Organization recently created a priority list of dangerous fungi to help doctors and researchers focus their efforts. This review discusses how this list can improve diagnosis, testing, and treatment of fungal infections across Europe, while also highlighting the need for better training and awareness among healthcare workers.

Estimated burden of serious mycoses in Poland

mycolabadmin

This study reveals that Poland has a significant but underreported problem with serious fungal infections affecting thousands of people annually. The most common fungal infections are yeast infections like candidosis, while mold infections like aspergillosis are the most serious in immunocompromised patients. The research shows that current reporting systems severely underestimate the true burden of these infections, highlighting the need for better surveillance and diagnostic practices.

Diversity and Distribution of Fungal Infections in Rwanda: High Risk and Gaps in Knowledge, Policy, and Interventions

mycolabadmin

This comprehensive review reveals that Rwanda faces significant challenges from fungal infections affecting humans, crops, and food security, yet has very limited systems to detect, report, or manage these infections. The study found various dangerous fungi causing infections ranging from vaginal candidiasis to serious disseminated infections, as well as crop-destroying soil fungi threatening bean production. The researchers emphasize that Rwanda urgently needs better diagnostic tools, trained healthcare workers, and coordinated public health strategies to combat the growing threat of fungal diseases.

Recent innovations and challenges in the treatment of fungal infections

mycolabadmin

Fungal infections are becoming more common and harder to treat due to drug resistance, especially in people with weakened immune systems. Current antifungal medications are becoming less effective because fungi are adapting to resist them, and these drugs can cause serious side effects. Scientists are developing new treatment strategies using combinations of existing drugs, engineered biological approaches, and specially designed delivery systems to overcome resistance and improve patient outcomes.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

Dr. John Perfect, a leading infectious disease expert, discusses his 48-year career studying fungal infections, particularly cryptococcal meningitis. He reflects on the dramatic transformation of HIV/AIDS from a fatal disease to a manageable chronic condition and emphasizes that antifungal resistance is less concerning than the underlying diseases that complicate treatment. Perfect advocates for developing more potent antifungal drugs that work faster, and discusses promising approaches like molecular diagnostics and immune-based therapies to improve patient outcomes.

Disease: Pneumocystis pneumonia